Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOGUG-NEOWIN neoadjuvant erdafitinib with or without cetrelimab in FGFR-altered cisplatin-ineligible muscle-invasive bladder cancer
2024-512573-27-01Phase 2Authorised
- Sponsor
- SOGUG
- Start
- Aug 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of erdafitinib and cetrelimab in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC) (2 arms), sponsored by SOGUG. Primary endpoints: Pathological complete response and Pathological downstaging < ypT2. Planned start Aug 2024; status: authorised.
02
Drugs
erdafitinibcetrelimab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-512573-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512573-27-01.